Latest Bevacizumab Stories
In-demand research report “Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM”
Ophthotech/Novartis's Fovista Will Exceed $500 Million in 2023 Sales as a Treatment for the Wet Form of the Disease, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
TARRYTOWN, N.Y., Oct. 17, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
Analyses of PRiDe, a registry of 457 recurrent glioblastoma patients, show that patients treated with the NovoTTF(TM)-100A System at their first and second recurrences had median overall survivals
-- Phase III RAINBOW Trial Data Published in The Lancet Oncology -- INDIANAPOLIS, Sept.
-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept.
Introduction of Extended RAS Testing and Recent Clinical Trial Data Will Affect How Physicians Treat Colorectal Cancer Patients, According to Findings from Decision Resources Group BURLINGTON,
DelMar Is Advancing Clinical Trials With VAL-083 As A New Chemotherapy For Refractory Glioblastoma Multiforme VANCOUVER, British Columbia and MENLO PARK, Calif., Aug.
- The governor of a province or people.